<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335503">
  <stage>Registered</stage>
  <submitdate>19/05/2010</submitdate>
  <approvaldate>24/08/2010</approvaldate>
  <actrnumber>ACTRN12610000696099</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artesunate+sulfadoxine/pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in At Tur Bani Qa'is, Harad, Almusaymir, Jabal Ash Sharq, Al Udayn and Bajil districts in Yemen</studytitle>
    <scientifictitle>Efficacy and safety of artesunate+sulfadoxine/pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Yemen</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One-arm propective evaluation with:
(a) artesunate+sulfadoxine/pyrimethamine combination therapy in 4 sites (Al Tor beni Qais, Harad, Almosaimeer, Al Odein) and 
(b) artemether-lumefantrine combination therapy in two sites (Jabal Al Sharq and Bajil).

Dose regimen:
(a) artesunate+sulfadoxine/pyrimethamine tablets:  artesunate 4 mg/kg body weight (bw) per day for 3 days plus a single dose of 25/1.25 mg/kg bw of sulfadoxine/ pyrimethamine.

(b) artemether-lumefantrine tablets (tablet containing artemether 20 mg/lumefantrine 120 mg):  6-dose regimen of artemether-lumefantrine twice a day for 3 days according to the following weigth bands: 
5-14 kg bw: 1 tablet; 15-24 kg bw: 2 tablets; 25-34 kg bw: 3 tablets and =35 kg bw: 4 tablets.

All treatment will be orally taken tablets</interventions>
    <comparator>uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>% of artesunate+sulfadoxine/pyrimethamine treatment failure (early treatment failure+late clinical failure+late parasitological failure)

Enrolled patients will be assessed for parasitological (using microscopy) and clinical responses during the 28 days follow-up and treatmnt outcomes will be classified according to the latest WHO protocol (http://www.who.int/malaria/publications/atoz/9789241597531/en/index.html).</outcome>
      <timepoint>At 28 day following treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>% of artemether-lumefantrine treatment failure  (early treatment failure+late clinical failure+late parasitological failure).
Enrolled patients will be assessed for parasitological (using microscopy) and clinical responses during the 28 days follow-up and treatmnt outcomes will be classified according to the latest WHO protocol (http://www.who.int/malaria/publications/atoz/9789241597531/en/index.html).</outcome>
      <timepoint>At 28 day following treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>% of adverse events in the artesunate+sulfadoxine/ pyrimethamine and artemether-lumefantrine treated groups.


All patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. All adverse events will be recorded on the case report form.</outcome>
      <timepoint>At 28 day following treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	age 6 months and above; 
2.	mono-infection with Plasmodium falciparum  (P.falciparum) detected by microscopy;
3.	parasitaemia of 500-200000/microliter asexual forms;
4.	presence of axillary temperature less than or equal to 37.5 degrees centigrade;
5.	ability to swallow oral medication;
6.	ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
7.	informed consent from the patient or from a parent or guardian in the case of children.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of World Health Organization (WHO).
2.	mixed or mono-infection with another Plasmodium species detected by microscopy;
3.	presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference &lt;110 mm);
4.	presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, Human immunodeficiency virus/Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (HIV/AIDS);
5.	regular medication, which may interfere with antimalarial pharmacokinetics;
6.	history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); 
7.	unmarried women of child-bearing age;
8.	a positive pregnancy test or breastfeeding;
9.	unable to or unwilling to take contraceptives for pregnancy negative married women of child-bearing age.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>NA</concealment>
    <sequence>NA</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2009</anticipatedstartdate>
    <actualstartdate>8/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/02/2011</actualenddate>
    <samplesize>522</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Yemen</country>
      <state>Hajja Governorate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Yemen</country>
      <state>Al-Hudeida Governorate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Yemen</country>
      <state>Ibb Governorate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Yemen</country>
      <state>Dhamar Governorate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Yemen</country>
      <state>Lahj Governorate</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Public Health and Population</primarysponsorname>
    <primarysponsoraddress>P.O. Box: 16544, Sana'a</primarysponsoraddress>
    <primarysponsorcountry>Yemen</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Public Health and population</fundingname>
      <fundingaddress>P.O. Box: 16544, Sana'a</fundingaddress>
      <fundingcountry>Yemen</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>None</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>World Health organization</othercollaboratorname>
      <othercollaboratoraddress>20 Av. Appia, 1211 Geneva 27 Switzerland</othercollaboratoraddress>
      <othercollaboratorcountry>Switzerland</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study assesses the efficacy and safety of artesunate+sulfadoxine/pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated P. falciparum infections in The participants will be febrile patients aged 6 months and above with confirmed uncomplicated P. falciparum infection. Artesunate (4mg/kg over 3 days) co-administered with sulfadoxine/pyrimethamine (single dose of 25mg sulfadoxine/1.25mg pyrimethamine per kg on day 0) will be tested in four of the sites and artemether-lumefantrine (a 6-dose regimen of artemether-lumefantrine twice a day for 3 days) in the other two sites. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy. The study will be conducted from November 2009 to April 2010.</summary>
    <trialwebsite />
    <publication>The data from the study was communicated to Ministry of health. No peer reviewed publication has been published yet.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>General Doctorate for Research and Studies</ethicname>
      <ethicaddress>P.O. Box: 16544, Sana'a</ethicaddress>
      <ethicapprovaldate>12/10/2009</ethicapprovaldate>
      <hrec>64</hrec>
      <ethicsubmitdate />
      <ethiccountry>Yemen</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>WHO Ethical Review Committee (ERC)</ethicname>
      <ethicaddress>20 Av. Appia, 
1211 Geneva 27 Switzerland</ethicaddress>
      <ethicapprovaldate>21/01/2010</ethicapprovaldate>
      <hrec>RPC372</hrec>
      <ethicsubmitdate>11/12/2009</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Fathi Ali Mohammed Hizam</name>
      <address>National Malaria Control Programme, P.O. Box:  16544, Sana'a</address>
      <phone>+967 1626107</phone>
      <fax />
      <email>fathihizam@gmail.com</email>
      <country>Yemen</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Mohamed Abdullah Al-Henemi</name>
      <address>National Malaria Control Programme, P.O. Box:  16544, Sana'a</address>
      <phone>+9671626107</phone>
      <fax />
      <email>henami2@hotmail.com</email>
      <country>Yemen</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Fathi Ali Mohammed Hizam</name>
      <address>National Malaria Control Programme, P.O. Box:  16544, Sana'a</address>
      <phone />
      <fax />
      <email>fathihizam@gmail.com</email>
      <country>Yemen</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Fathi Ali Mohammed Hizam</name>
      <address>National Malaria Control Programme, 
Ministry of Public Health &amp; Population
PO Box:  16544, Sana'a, Yemen.
Sana'a
Yemen
</address>
      <phone>+967 1626107</phone>
      <fax />
      <email>fathihizam@gmail.com</email>
      <country>Yemen</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>